Terapia hormonal y la ventana de oportunidad: qué cambió tras el WHI

What happened in 2002

The Women's Health Initiative was the largest randomised trial of hormone therapy ever conducted, and its 2002 publication changed practice almost overnight. Reported increases in breast cancer and cardiovascular risk among women taking oral conjugated equine estrogens with medroxyprogesterone acetate led millions of women to stop treatment and a generation of physicians to stop offering it. The reaction was understandable. It was also, in retrospect, insufficiently precise — because the average participant was well past the menopausal transition, and the result was applied to women who were not.

The reanalysis that mattered

Subanalysis by age group showed that the elevated coronary heart disease risk applied mainly to women who began therapy after age 60 or more than a decade past menopause. Eighteen-year follow-up data showed no difference in all-cause or cause-specific mortality between treated and untreated groups. Two dedicated trials — ELITE and KEEPS — subsequently examined earlier initiation and found a more favourable vascular profile when therapy began closer to the transition. This is the origin of what is now called the timing hypothesis.

What the timing hypothesis claims

The proposition is that the same intervention produces different results depending on the state of the vasculature when it starts. Initiated near menopause, when arteries are relatively healthy, estrogen appears vascularly neutral or favourable. Initiated a decade or more later, into arteries with established atherosclerotic plaque, it appears to carry more hazard. A parallel idea, the healthy cell bias hypothesis, applies the same logic to neurons and cognitive outcomes. Both remain hypotheses supported by subgroup and secondary analyses rather than by a trial designed to test them directly, which is precisely how they should be described.

Where current guidance sits

Professional societies now endorse menopausal hormone therapy for symptomatic women under 60 or within 10 years of menopause who lack contraindications such as breast cancer, active thromboembolic disease or uncontrolled cardiovascular disease. Guidance emphasises shared decision-making, the lowest effective dose, and periodic reassessment. Therapy is first-line for moderate to severe vasomotor symptoms and for genitourinary syndrome of menopause, and it prevents early postmenopausal bone loss. Cardiovascular prevention is explicitly not an indication — an important distinction that gets lost in enthusiastic marketing.

Route and dose are not details

Contemporary practice has moved away from a single regimen. Transdermal estradiol avoids first-pass hepatic metabolism and is generally favoured over oral where thrombotic or cardiometabolic risk is salient. Low-dose vaginal estrogen is highly effective for genitourinary symptoms with minimal systemic exposure. Progestogen choice matters for endometrial protection and for the breast risk profile. Dose is titrated to symptom control and tolerability, not to a target laboratory value. These decisions are where individualisation actually happens.

What bioidentical does and does not mean

Bioidentical means the hormone molecule is structurally identical to the one your body produces — estradiol, progesterone. Several FDA-approved products meet that definition. The term is also used to market custom compounded preparations, which are a different proposition: compounded formulations are not FDA-approved, their dosing is less consistent, and salivary hormone monitoring has no validated role in guiding them. We prescribe bioidentical hormones. We are specific about which product, why, and what evidence supports it.

Men are a separate conversation

Testosterone therapy in men has its own evidence base, its own indications and its own risks, and it should not be reasoned about by analogy to menopausal hormone therapy. It requires confirmed low morning testosterone on repeated measurement alongside consistent symptoms, evaluation of reversible causes, and monitoring of haematocrit, prostate-specific antigen and cardiovascular risk. Fatigue alone is not a diagnosis, and treating a number in an asymptomatic man is not good medicine.

How we approach it

A full history and symptom inventory. Comprehensive labs. An explicit discussion of what the evidence supports for your age, time since menopause and risk profile — including the case for not treating. If we proceed, the lowest effective dose by the route that suits your risk, with follow-up testing and periodic reassessment of whether continuing still makes sense. When individually indicated, dosed and monitored, hormone therapy has a well-studied safety profile. Your physician reviews the risks and benefits for your specific case.